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The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45
neg myeloma cells.
AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support
the therapeutic use of anti-IGF-1R/bortezomib in CD45
neg Myeloma patients, particularly those with the most aggressive form,
t(4,14).
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The therapeutic use of monoclonal antibodies (mAb) has emerged as
a very potent clinical strategy in the treatment of cancer
(Houshmand and Zlotnik, 2003; Hudis, 2007). In multiple myeloma
(MM), we previously demonstrated that an antagonistic anti-IGF-1R
mAb (EM164, also named mAVE1642) can selectively inhibit the
growth of CD45
neg human myeloma cell lines (HMCLs) (Descamps
et al, 2006). MM is an incurable plasma-cell malignancy. The
subgroup of MM patients lacking CD45 is associated with less
favourable clinical outcomes that require new treatments (Moreau
et al, 2004). Furthermore, it was shown that HMCL and MM patients
with either t(4,14) or t(14,16) chromosomal translocations expressed
a higher level of IGF-1R (Bataille et al, 2005). We previously
demonstrated that EM164 selectively inhibits IGF-1R but not insulin
signalling in myeloma cells (Descamps et al, 2006). Thus, EM164
displays a very potent and specific effect of IGF-1R downregulation
and complete blockade of IGF1-induced Akt and Erk phosphory-
lation. Similar results with AVE1642 recently confirmed using
the fully human anti-IGF-1R antibody named A12 (Wu et al, 2007).
Furthermore, it was shown that the A12 antibody can reduce
angiogenesis as it inhibits the in vitro secretion of VEGF in HMCL
(Wu et al, 2007). Altogether, these studies strongly support the use of
EM164 in combination regimens.
In addition to alkylating agents and corticosteroids, bortezomib,
a highly selective and potent inhibitor of the 26S proteasome, has
emerged as a novel class of potent agents in the treatment of MM
(Richardson et al, 2006a). In this study, we investigated the effects
of bortezomib and AVE1642 in combination on the induction of
apoptosis in HMCLs. Our group previously reported that
bortezomib-induced apoptosis in HMCLs was associated with
Noxa (a BH3-only protein) upregulation (Gomez-Bougie et al,
2007). Therefore, in the present study, we also examined the
impact on Noxa of the combination of bortezomib with AVE1642.
MATERIALS AND METHODS
Monoclonal antibodies and reagents
The anti-IGF-1R mAb AVE1642 was kindly provided by Sanofi-
Aventis/Immunogen (Vitry sur Seine, France). r-IL-6 was from
Novartis (Basel, Switzerland). The mAb against Noxa was from
Alexis Biochemicals (Nottingham, UK). The antibody against
caspase-3 (mouse mAb) was from Santa Cruz Biotechnology
(Tebu-Bio, Le Perray en Yvelines, France). Anti-actin mAb was
purchased from Chemicon International (Temecula, CA, USA).
Cell culture conditions
We used LP-1, NCI-H929 and JIM-3 human myeloma cell lines and
the IL-6-dependent human myeloma cell lines XG-1, XG-6, BCN
and NAN-3 HMCL. Cell lines were grown as described earlier
(Descamps et al, 2006). The characteristics and phenotypes of
these HMCLs have been recently reviewed by Bataille et al, 2006.
Cell viability and detection of apoptotic cells
Cell viability was determined by vital dye (0.4%. eosin) exclusion
and assessed by visual inspection in a haemocytometer. Cell death
was assessed by Apo 2.7 staining (Beckman Coulter, Roissy,
France) or by annexin V staining (Beckman Coulter) according to
the manufacturer’s recommendation. Flow cytometry analysis was
performed on a FACSCalibur using the Cell Quest software (Becton
Dickinson, San Jose, CA, USA).
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sProliferation assays
Myeloma cells (10
4 cells per well) were cultured in triplicate in 96-
well plates for 72h. Cells were pulsed with 1mCi [
3H] thymidine
during the last 8 hours of culture, harvested onto glass filters with
an automatic cell harvester (Perkin Elmer, Courtaboeuf, France),
and the uptake of [
3H] thymidine was monitored using a 1450-
Microbeta Jet b-counter (Perkin Elmer).
Protein extraction and western blot analysis
Western blot analysis of total cell lysates was performed according
to published protocols (Descamps et al, 2006). Immunoblots
were done using anti-Noxa, anti-caspase-3 and anti-actin
antibodies.
Statistical analysis
For statistical analysis, we used the non-parametric Spearman’s
rank test and the sign test.
RESULTS
In the present study, we used AVE1642, the humanised counterpart of
EM164 that displays the same selectivity to inhibit the IGF-1
signalling but has no effect on insulin pathway as demonstrated
earlier (Descamps et al, 2006). We have previously shown that EM164
strongly inhibits the growth of CD45
neg HMCLs, leading to a G1
growth arrest, whereas it has almost no effect on CD45
pos HMCL
growth (Descamps et al,2 0 0 6 ) .I nt h i ss t u d y ,w ed e m o n s t r a t e dt h a t
AVE1642 retains this selective activity toward CD45
neg HMCLs. After
4d a y so fi n c u b a t i o nw i t h5mgml
 1 of AVE1642, we observed growth
inhibition ranging from 60 to 99% for the five CD45
neg HMCLs (BCN,
NAN-3, LP1, NCI-H929 and JIM-3). In contrast, a very weak growth
inhibition was observed for XG-1 and XG-6 CD45
pos HMCLs, at
13±10% and 12±10%, respectively (Figure 1A). Interestingly, we
observed that the CD45
neg HMCLs had either a t(4,14) (n¼4) or
t(14,16) chromosomal translocation (n¼1). We found that AVE1642
treatment did not induce any apoptosis in HMCLs, measured both by
Apo2.7 and annexin staining, regardless of CD45 status, with the
exception of JIM-3, where AVE1642 induced 50±4% of apoptotic
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Figure 1 (A) Sensitivity of HMCLs to AVE1642 and bortezomib. Myeloma cells were cultured in the presence or absence of AVE1642 (5mgml
 1) for 3
days. For the IL-6-dependent HMCLs (XG-1, XG-6, BCN and NAN-3) 3ngml
 1 of IL-6 was added. Results are shown as mean (±s.d.) of percent
proliferation inhibition by [
3H] thymidine incorporation of triplicate cultures, compared with the untreated control. For Bortezomib sensitivity, cells were
treated with 10nM of bortezomib for 48h in culture conditions. Then, cell death was assessed by Apo 2.7 staining.(B) Bortezomib in association with
AVE1642 is more efficiently able to induce apoptosis of CD45
neg HMCLs than bortezomib alone. Myeloma cells were pre-incubated in RPMI-1640 with 5%
FCS in the absence or presence of AVE1642 (5mgml
 1) for 24h. For the IL-6-dependent HMCLs (BCN, NAN-3, XG-1 and XG-6), 3ngml
 1 of IL-6 is
added. Then, cells were treated with different concentrations of bortezomib in the absence or presence of AVE1642 (5mgml
 1) for an additional 48h. Cells
were stained with Apo2.7-PE. (C) Bortezomib LD50 and LD80 in the presence or not of AVE1642. Myeloma cells were treated as above and LD50 and
LD80 were determined.
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scells (Figure 1B). Of note, JIM-3 has been reported to express very
high IGF-1R levels (Descamps et al, 2006), which may explain its
survival addiction to this target. Bortezomib has been shown to
induce apoptosis in MM. As shown earlier (Gomez-Bougie et al,
2007), measurement of bortezomib activity using Apo2.7 staining
confirmed that HMCLs exhibit different sensitivities to bortezomib
treatment. HMCLs can be classified as follows: high sensitivity (NCI-
H929, XG-1), intermediate sensitivity (NAN-3, BCN and XG-6) and
w e a ks e n s i t i v i t y( L P 1a n dJ I M - 3 ) .O fi n t e r e s t ,o u rr e s u l t ss h o wa
strong statistical inverse correlation between bortezomib apoptosis
induction and AVE1642 growth inhibition in this fairly large panel of
HMCLs (P¼0.042, Spearman’s test). We then tested whether
AVE1642 was able to enhance bortezomib-induced apoptosis.
AVE1642 significantly enhanced bortezomib-induced apoptosis in
all CD45
neg HMCLs (Figure 1B). Moreover, a pretreatment with
AVE1642 for 24h was more efficient than simultaneous treatment
with AVE1642/bortezomib (data not shown). Increased apoptosis
induction due to the AVE1642/bortezomib combination was
independent of the bortezomib sensitivity status of HMCL, but was
significantly correlated with the AVE1642 sensitivity (P¼0.038). As
expected, the AVE1642/bortezomib combination did not modify
bortezomib-induced apoptosis in CD45
pos HMCLs. After determina-
tion of the bortezomib LD50 and LD80 (bortezomib concentrations
where 50 and 80% of cells are stained with Apo2.7, respectively), we
measured the impact of AVE1642 addition on those values. In
CD45
neg HMCLs, but not in CD45
pos HMCLs, addition of AVE1642
induced significant decreases in the bortezomib LD50 and LD80
values. More specifically, Figure 1C shows that bortezomib LD80
values were statistically shifted from 424 to 14nM to less than 10nM
(Po0.05). Altogether, these results demonstrate synergy between
bortezomib and AVE1642 in CD45
neg HMCLs.
Our group has recently pinpointed mechanisms by which
bortezomib promotes apoptosis, showing that Noxa induction is
linked to bortezomib-induced apoptosis (Gomez-Bougie et al, 2007).
BH3-only Noxa is a sensitiser molecule that induces the release of
BH3-only activators that are responsible for Bax activation and
activation of the mitochondrial apoptotic pathway (Letai et al,
2002). In NAN-3 HMCLs, we confirmed that bortezomib-induced
apoptosis was associated with Noxa upregulation. Figure 2 shows
that this upregulation was strongly increased by the addition of
AVE1642 to CD45
neg HMCLs, whereas this upregulation was not
detected in CD45
pos HMCLs (result not shown).
In JIM3 HMCLs, a moderate Noxa protein increase was also
observed by AVE1642 alone; however, the combination of
AVE1642 with bortezomib led to stronger Noxa upregulation.
Noxa upregulation was associated with caspase-dependent cell
death, as shown by caspase3 activation (detected by p17 cleaved
fragment). Moreover, in JIM-3 HMCLs, a significant cleavage of
caspase3 was observed with AVE1642 alone, coinciding with
moderate apoptosis and Noxa induction (Figure 2).
DISCUSSION
This study demonstrates synergy between bortezomib and
AVE1642 for apoptosis induction in CD45
neg HMCLs. Indeed, we
have shown earlier that the presence of the CD45 phosphatase
inhibits IGF-1 signalling by a direct interaction between CD45
and IGF-1R, which probably dephosphorylates IGF-1R and results
in an inhibition of IGF-1 signalling. This may explain the restricted
effect of the combination of bortezomib and AVE1642 on CD45
neg
HMCLs. Of note, CD45
neg HMCLs specifically include HMCLs with
the most aggressive 14q32 translocations (t(4,14) and t(14,16)),
and these also present higher levels of IGF-1R expression (Bataille
et al, 2005). Altogether, we showed that the combination of
bortezomib and AVE1642 may be particularly an efficient strategy
for CD45
neg HMCLs having the translocations t(4,14) and t(14,16)
and thus expressing the highest IGF-1R levels. Furthermore, our
CD45
neg HMCL panel shows that the increased potency of
bortezomib when combined with AVE1642 is directly related to
the sensitivity of the individual cell line to AVE1642. Finally, we
show that AVE1642 strongly increases bortezomib-induced
apoptosis in correlation with an increase of both Noxa expression
and caspase-3 activation. Furthermore, Noxa induction levels
were correlated with the increased apoptotic effect of the
AVE1642/bortezomib combination. This result emphasises the
importance of Noxa as a sensitiser molecule that is able to induce
the release of the BH3-only activators that are responsible for Bax
activation.
Taken together, these results suggest that the combination of
anti-IGF-1R therapies with bortezomib treatment could be
beneficial for MM patients and may be particularly useful for
the subpopulation of patients lacking CD45. Of note, this
association could provide significant improvements in the
treatment of the most aggressive and resistant forms of MM,
those with t(4,14). These forms of MM are characterised by
both the lack of CD45 and a high expression of IGF-1R (Bataille
et al 2005). In addition, this treatment strategy may help
to improve the management of bortezomib dosage in a clinical
setting as this agent has a very narrow therapeutic window and can
induce severe peripheral sensory neuropathy (Richardson et al,
2006b).
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